Group 1 - Medtronic's stock price has declined for two consecutive days, totaling a drop of 3.35%, reaching a new low since July 2025, which has attracted market attention [1] - Elliott Management has become a significant shareholder in Medtronic, advocating for changes in the company's governance structure, including the addition of two independent directors and the establishment of a special committee focused on growth and operations [1] - Despite Medtronic's Q1 FY2026 revenue of $8.6 billion, which exceeded market expectations of $8.4 billion, the stock price did not respond positively, indicating that the market may have already priced in the good news [1] Group 2 - Medtronic's recent actions reflect a proactive approach to seeking transformation through governance adjustments and sustained performance growth to enhance overall competitiveness [2] - Investors should monitor the subsequent impacts of these reforms and their support for the long-term development of the company's core business [2] - The stock price fluctuations of Medtronic illustrate the market's digestion process regarding the company's governance changes and performance [2]